Ranibizumab BS (ranibizumab biosimilar) - Noritsu Koki, Senju Pharmaceutical
Lucentis (ranibizumab) - Roche, Novartis
Non-inferiority study of the efficacy of ranibizumab BS compared with aflibercept in patients with macular oedema due to untreated branch retinal vein occlusion: REMEDY-BRVO study - study protocol. (PubMed, BMJ Open Ophthalmol) - Oct 16, 2026 - No abstract available 
Head-to-Head • Journal • Macular Edema • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion
http://www.ncbi.nlm.nih.gov/pubmed/42880818
 
Ai Toride; Atsuhide Takesue; Ayumi Ouchi-Usui; Daisuke Takami; Gaku Ishida; Kazutaka Adachi; Kenta Ashikaga; Koichi Ono; Shintaro Nakao; Shutaro Yamamoto; Takanori Nakagawa; Tetsuya Tajika; Toshiaki Hirakata; Toshihiko Ohta; Yoshimune Hiratsuka; Yoshinari Sadamatsu
 
Oct 16, 2026
 
Prev Next